Proprietary AI analyst is now available

MeiraGTx Valuation Multiples

Discover MeiraGTx's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Akums Drugs and Pharma, ACROBiosystems, TchaikaPharma, Xencor and more.

MeiraGTx Overview

About MeiraGTx

MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.


Founded

2018

HQ

United Kingdom

Employees

425

Financials (LTM)

Revenue: $67M
Net Income: ($138M)

EV

$980M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

MeiraGTx Financials

MeiraGTx reported last 12-month revenue of $67M.

In the same LTM period, MeiraGTx generated $65M in gross profit and had net loss of ($138M).

Revenue (LTM)


MeiraGTx P&L

In the most recent fiscal year, MeiraGTx reported revenue of $81M and EBITDA of ($89M).

MeiraGTx is unprofitable as of last fiscal year, with gross margin of 94%, EBITDA margin of (110%), and net margin of (140%).

See analyst estimates for MeiraGTx
LTMLast FY202320242025202620272028
Revenue$67M$81M$14M$33M$81M
Gross Profit$65M$77M-$9M$77M
Gross Margin97%94%-29%94%
EBITDA-($89M)($57M)($122M)($89M)
EBITDA Margin-(110%)(407%)(366%)(110%)
EBIT Margin(209%)(130%)(978%)(493%)(130%)
Net Profit($138M)($114M)($84M)($148M)($114M)
Net Margin(208%)(140%)(599%)(444%)(140%)
Net Debt-$8M---

Financial data powered by Morningstar, Inc.

MeiraGTx Stock Performance

MeiraGTx has current market cap of $964M, and enterprise value of $980M.

Market Cap Evolution


MeiraGTx's stock price is $10.41.

MeiraGTx share price decreased by 2.3% in the last 30 days, and increased by 59.7% in the last year.

MeiraGTx has an EPS (earnings per share) of $-1.23.

See more trading valuation data for MeiraGTx
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$980M$964M7.1%-2.3%20.2%59.7%$-1.23

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

MeiraGTx Valuation Multiples

MeiraGTx trades at 14.7x EV/Revenue multiple, and (11.0x) EV/EBITDA.

See NTM and 2027E valuation multiples for MeiraGTx

EV / Revenue (LTM)


MeiraGTx Financial Valuation Multiples

As of June 18, 2026, MeiraGTx has market cap of $964M and EV of $980M.

MeiraGTx has a P/E ratio of (7.0x).

LTMLast FY202320242025202620272028
EV/Revenue14.7x12.0x69.9x29.4x12.0x
EV/EBITDA-(11.0x)(17.2x)(8.0x)(11.0x)
EV/EBIT(7.1x)(9.2x)(7.2x)(6.0x)(9.2x)
EV/Gross Profit15.2x12.8x-103.3x12.8x
P/E(7.0x)(8.4x)(11.5x)(6.5x)(8.4x)
EV/FCF-(19.4x)(7.8x)(9.0x)(19.4x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified MeiraGTx Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

MeiraGTx Margins & Growth Rates

MeiraGTx decreased revenue by 39% and EBITDA by 104% in the last fiscal year.

In the most recent fiscal year, MeiraGTx reported gross margin of 94%, EBITDA margin of (110%), and net margin of (140%).

See estimated margins and future growth rates for MeiraGTx

MeiraGTx Margins

Last FY202420252026202720282029
Gross Margin94%29%94%100%
EBITDA Margin(110%)(366%)(110%)8%
EBIT Margin(130%)(493%)(130%)(359%)
Net Margin(140%)(444%)(140%)(337%)
FCF Margin(62%)(329%)(62%)-

MeiraGTx Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(39%)137%145%(39%)
Gross Profit Growth(36%)-707%(36%)
EBITDA Growth(104%)114%(27%)(104%)
EBIT Growth67%20%(35%)67%
Net Profit Growth46%76%(23%)46%
FCF Growth-(13%)(54%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

MeiraGTx Operational KPIs

MeiraGTx's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.4M for the same period.

MeiraGTx's Rule of 40 is (32%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

MeiraGTx's Rule of X is (91%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for MeiraGTx
LTMLast FY202320242025202620272028
Rule of 40-(32%)---
Bessemer Rule of X-(91%)---
Revenue per Employee-$0.2M---
Opex per Employee-$0.4M---
G&A Expenses to Revenue69%65%337%163%65%
R&D Expenses to Revenue197%159%740%359%159%
Opex to Revenue-224%1078%522%224%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Akums Drugs and Pharma1.7x1.7x11.9x13.6x
ACROBiosystems6.2x5.5x21.7x20.0x
TchaikaPharma25.3x-162.4x-
Xencor5.4x6.8x(14.4x)(3.4x)
Mega Lifesciences1.8x1.8x8.2x8.1x
ARS Pharmaceuticals10.4x7.7x(5.2x)-
SPIMACO - ADDWAEIH2.6x2.6x10.9x12.1x
Daewoong Pharmaceutical1.4x1.4x8.4x8.7x

This data is available for Pro users. Sign up to see all MeiraGTx competitors and their valuation data.

Start Free Trial

MeiraGTx VC Funding History

Before going public, MeiraGTx raised $8M in total equity funding, across 2 rounds.

Last private valuation of MeiraGTx was $65M, after raising $5M in March 2018 from Essex Bio-Technology.


MeiraGTx Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Mar-18Series BEssex Bio-Technology$5M$65MMeiraGTx is a clinical-stage biotech company incorporated in England and Wales, developing novel gene therapy treatments for inherited and acquired ocular diseases, xerostomia following radiation for head and neck cancers, and neurodegenerative diseases such as amyotrophic lateral sclerosis. Essex Bio-Technology invested approximately $5 million to subscribe for about 7.7% of MeiraGTx's enlarged issued preferred C shares around March 2018. This implies a post-money valuation of approximately $65 million. MeiraGTx successfully listed on the NASDAQ Stock Market on June 8, 2018, under stock code MGTX, with the preferred C shares converting to 1.76% of the fully enlarged share capital upon listing. On June 12, 2018, the company completed its IPO, selling 5,000,000 shares of common stock at $15.00 per share. As of December 31, 2018, MeiraGTx reported cash and cash equivalents of $68.1 million.
Dec-17SeedAlbionVC; ATW Partners; UCL Technology Fund$3M--

Acquisitions by MeiraGTx

MeiraGTx has acquired 2 companies to date.

Last acquisition by MeiraGTx was on October 17th 2019. MeiraGTx acquired MeiraGTx for $1M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by MeiraGTx

MeiraGTx
Vector Neurosciences
Description
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
-
HQ CountryUnited Kingdom-
HQ City
Amsterdam
-
Deal Date17 Oct 20195 Oct 2018
Valuation$1M$24M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all MeiraGTx acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by MeiraGTx

MeiraGTx has invested in 1 company to date.

Latest investment by MeiraGTx was on September 30th 2025. MeiraGTx invested in Hologen Neuro AI in their $30M Strategic investment round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by MeiraGTx

Hologen Neuro AI
Description
Hologen Neuro AI is a joint venture between MeiraGTx and Hologen developing AAV-GAD gene therapies for neurological disorders. London and New York-based, the company advances clinical trials for Parkinson's disease treatment via adeno-associated virus vectors expressing GAD enzyme. Hologen Neuro AI's platform targets GABAergic neurons to restore motor function. Phase 1 studies report safety in 20 patients with dosing at multiple brain sites.
HQ CountryUnited Kingdom
HQ City
London
Deal Date30 Sep 2025
RoundStrategic investment
Raised$30M
InvestorsMeiraGTx
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all MeiraGTx investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About MeiraGTx

When was MeiraGTx founded?MeiraGTx was founded in 2018.
Where is MeiraGTx headquartered?MeiraGTx is headquartered in United Kingdom.
How many employees does MeiraGTx have?As of today, MeiraGTx has over 425 employees.
Who is the CEO of MeiraGTx?MeiraGTx's CEO is Alexandria Forbes.
Is MeiraGTx publicly listed?Yes, MeiraGTx is a public company listed on Nasdaq.
What is the stock symbol of MeiraGTx?MeiraGTx trades under MGTX ticker.
When did MeiraGTx go public?MeiraGTx went public in 2018.
Who are competitors of MeiraGTx?MeiraGTx main competitors include Akums Drugs and Pharma, ACROBiosystems, TchaikaPharma, Xencor, Mega Lifesciences, ARS Pharmaceuticals, SPIMACO - ADDWAEIH, Daewoong Pharmaceutical, GuangYuYuan Chinese, China TCM.
What is the current market cap of MeiraGTx?MeiraGTx's current market cap is $964M.
What is the current revenue of MeiraGTx?MeiraGTx's last 12 months revenue is $67M.
What is the current revenue growth of MeiraGTx?MeiraGTx revenue growth (NTM/LTM) is 8%.
What is the current EV/Revenue multiple of MeiraGTx?Current revenue multiple of MeiraGTx is 14.7x.
Is MeiraGTx profitable?No, MeiraGTx is not profitable.
What is the current net income of MeiraGTx?MeiraGTx's last 12 months net income is ($138M).
How many companies MeiraGTx has acquired to date?As of June 2026, MeiraGTx has acquired 2 companies.
What was the largest acquisition by MeiraGTx?$24M acquisition of Vector Neurosciences on 5th October 2018 was the largest M&A MeiraGTx has done to date.
What companies MeiraGTx acquired?MeiraGTx acquired Vector Neurosciences and MeiraGTx.
In how many companies MeiraGTx has invested to date?As of June 2026, MeiraGTx has invested in 1 company.
What was the last MeiraGTx investment?On 30th September 2025 MeiraGTx invested in Hologen Neuro AI, participating in a $30M Strategic investment round.
In what companies MeiraGTx invested in?MeiraGTx invested in Hologen Neuro AI.

See public comps similar to MeiraGTx

Lists including MeiraGTx

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial